Company / Profit Margin
ENANTA PHARMACEUTICALS INC Profit Margin History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Profit Margin
-168.9%
FY2025
5-year range
-168.9% / 22.6%
FY2021-FY2025
Trend
-19.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Profit Margin has declined for 5 consecutive years, from 34.8% in FY2020 to -168.9% in FY2025.
Based on SEC 10-K filings.
-168.9% in FY2025 with a 5-year CAGR of -203.8%.
Declined from -81.4% to -168.9% over the past 2 years.
Profit Margin over time
Growth rates
- 3-Year Change
- -139.4pp
- 5-Year Change
- -203.8pp
- 10-Year Change
- -
Key checks
Key Insights
- ENANTA PHARMACEUTICALS INC's profit margin has declined for 5 consecutive years.
- In FY2025, profit margin decreased 19.6% year-over-year.
- Peak profit margin was recorded in FY2016.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.48 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Profit MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | -168.9% | -19.6% |
| FY2024 | -141.3% | -73.6% |
| FY2023 | -81.4% | -175.6% |
| FY2022 | -29.5% | -230.7% |
| FY2021 | 22.6% | -35.1% |
| FY2020 | 34.8% | +102.1% |
| FY2019 | 17.2% | -29.8% |
| FY2018 | 24.6% | -50.0% |
| FY2017 | 49.1% | -31.9% |
| FY2016 | 72.1% | +140.2% |
As of FY2025 · SEC 10-K · Updated Jun 24, 2026